this one is in PLAYCB2 Insights Announces Record Revenue of $4.2 million for the Third Quarter 2019; Sequential Growth of 29% TORONTO, Nov. 08, 2019 -- CB2 Insights (CSE:CBII; OTCQB: CBIIF) (“CB2” or the “Company”), a leading data-driven company focused on bringing real-world evidence driven from the point-of-care to the medical cannabis community, announced its results for the three and nine months ended September 30, 2019. All figures are reported in Canadian dollars ($), unless otherwise indicated. CB2 Insights’ financials are prepared in accordance with International Financial Reporting Standards (“IFRS”). “This was a milestone quarter for us at CB2, it was the first full reporting period that included the contributions of all three clinical businesses. We now operate one of the largest networks in the US, serving more than 100,000 unique patients annually,” said Prad Sekar, CEO of CB2 Insights. “Beyond our clinical business, we started to see our technology and research and development services begin to materialize into revenue-generating divisions. The Company has now booked approximately a quarter of a million in trials that will commence over the next 6 months, with $4 million of opportunities in the pipeline. We continue to blend the three divisions to gather Real-World Data and provide Real-World Evidence with our global partners. Going forward, the Company will remain focused on transformative growth in all areas of our business. Therefore, giving us a clear path to profitability in the near future.” Financial highlights for the third quarter ended September 30, 2019 The following are the major financial highlights of CB2’s operating results for the three months ended September 30, 2019 compared to the three months ended June 30, 2019: • Revenue was $4.2 million for the quarter, compared to $3.3 million in the previous quarter, demonstrating an increase of 29%; • Gross profit was $2.9 million for the quarter, compared to $2.1 million, demonstrating an increase of 38%; • Operating expense was $3.7 million for the quarter, compared to $3.8 million, demonstrating a decrease of 2.6%; • Net loss of $1.1 million, compared to $1.9 million, demonstrating a 43% improvement; • Adjusted EBITDA1 loss $288,220, compared to Adjusted EBITDA loss of $790,818, demonstrating an improvement of 64%